To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …
I am very excited to announce the opening of a new Cellular Therapy by Tscan Therapeutics using TCR protocol at the Orlando Health Cancer Institute (OHCI) targeting Melanoma, Head/Neck Cancer, NSCLC, Ovarian, and HPV positive Anal-Cervical SCC. Information for this new open clinical trial was provided from a public source. Please reach out to Karin …
This post is based on the interesting results published by Routy et al. Nature July 2023. I am hoping that we will soon open a protocol using FMT in cancer patients and I will announce once we’re site activated at the Orlando Health Cancer Institute. The revolutionary world of cancer treatment is once again on …
Shifting the Paradigm of Cancer Treatment In previous posts on MedOncMD.com, I’ve discussed a message about a future where we rely less on traditional chemotherapy. Dr. Thomas and I have dedicated a significant portion of our careers to shifting the paradigm toward more targeted therapies that minimize damage to healthy cells. Our ultimate goal is …
Myeloproliferative disorders are a group of conditions characterized by overactivity in the bone marrow. Many of these conditions are driven by mutations in the JAK-2 gene (Janus Kinase 2 gene), which plays a crucial role in regulating the growth and production of cells in the bone marrow. While there are other mutations involved, JAK-2 mutations …
Traditional Treatment Approaches for Hodgkin’s Lymphoma Lymphomas encompass a diverse group of blood cancers, with various types and treatment approaches depending on factors such as lymphoma subtype, origin, and aggressiveness. One particular lymphoma subtype with unique treatment options is Hodgkin’s lymphoma. Traditionally, in the United States, Hodgkin’s lymphoma has been treated with a chemotherapy combination …
In the realm of oncology trials, we employ a severity rating system known as the Grade scale to assess toxicities. This scale helps us gauge whether a patient should modify or discontinue their treatment. The Grade scale consists of five points, ranging from mild toxicities to life-threatening ones.